<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201101049213N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-18</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Wet cupping on metabolic syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Wet cupping on known cardiovascular risk factors and anti-heat shock protein-27 in patients with metabolic syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-07-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>136</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51988</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Randomization description: In this randomized clinical trial study, after excluding criteria  136 patients will be recruited. Individuals will be randomized by PASS application and dual block randomization method. One hundred and thirty-six number will be divided into two groups ( A: Intervention group, B: Control group), the codes and names are written on a paper and are put in a paper packet. The first participant picks up packet number 1 and is guided to the respective group. Then the second participant picks up packet number 2 and the process continues until all participants are allocated.
Due to the type of treatment, there is no possibility of allocation concealment, and blindness could be only single-blind, Blinding description: All participants were not informed about the existence in the control or intervention groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Metabolic Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The diet and wet-cupping treatment were prescribed to the intervention group by a specialist. After a month, blood samples (20 cc) of the participants were taken and the diet and second wet-cupping treatment were prescribed to individuals again. After another month the last blood samples were taken from participants. Wet-cupping was performed by a physician or a trained person as general type. A swelling with a glass and a suction device was created, in the area between the two scapulae in the opposite side of the thymus gland, and thereafter, some superficial scratches were created on the skin parallel to the midline of the body with a distance of 3 to 5 mm between scratches. The length of each scratch was between 5 to 10 mm. 7 to 14 scratches were created, as they covered the entire cupping area. Finally, cupping was done in 3 to 5 consecutive stages; each stage lasted 3 to 5 minutes. At the end of cupping, 50 to 70 cc of the participant’s blood was taken, through dilatation and aspiration of capillaries. Then, the cupping area was completely covered with gas and glue. Intervention 2: Control group: The control group was recommended to follow a special diet for one month. Next (after 1 month), the second blood sample was taken from them. Then they followed the diet for another month. Finally, the third blood sample was taken from them.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad University of Medical Sciences, Azadi Square</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948564</zip>
        <telephone>+98 51 3800 2000</telephone>
        <email>mohammadim3@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kazem Farahmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi Square, Mashhad University of Medical Sciences</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948564</zip>
        <telephone>+98 51 3800 2000</telephone>
        <email>FarahmandK1@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having metabolic syndrome
Age range: 18 to 65 years old
Male or female
Resident in Mashhad city
Absence of consumption of any therapeutic diet and/or medication (antilipidemic medications)
Absence of infectious diseases or coagulopathies</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Ages under 18 and above 65 years old
Individuals with the history of stroke and ischemic heart disease
Consuming a specific therapeutic diet and/or medication
Diabetes mellitus type 1
Presence of any infectious disease based on the patient statement, but not be documented by laboratory tests</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E88.81</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Metabolic syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The diet and wet-cupping treatment were prescribed to the intervention group by a specialist. After a month, blood samples (20 cc) of the participants were taken and the diet and second wet-cupping treatment were prescribed to individuals again. After another month the last blood samples were taken from participants. Wet-cupping was performed by a physician or a trained person as general type. A swelling with a glass and a suction device was created, in the area between the two scapulae in the opposite side of the thymus gland, and thereafter, some superficial scratches were created on the skin parallel to the midline of the body with a distance of 3 to 5 mm between scratches. The length of each scratch was between 5 to 10 mm. 7 to 14 scratches were created, as they covered the entire cupping area. Finally, cupping was done in 3 to 5 consecutive stages; each stage lasted 3 to 5 minutes. At the end of cupping, 50 to 70 cc of the participant’s blood was taken, through dilatation and aspiration of capillaries. Then, the cupping area was completely covered with gas and glue.</i_keyword>
      <i_keyword>Control group: The control group was recommended to follow a special diet for one month. Next (after 1 month), the second blood sample was taken from them. Then they followed the diet for another month. Finally, the third blood sample was taken from them.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fasting Blood Glucose (FBG). Timepoint: Measurement of the FBG at the beginning of the study and a month, 2 months after finishing Wash Out Diet. Method of measurement: Blood sample.</prim_outcome>
      <prim_outcome>HDL. Timepoint: Measurement of the HDL at the beginning of the study and a month, 2 months after finishing Wash Out Diet. Method of measurement: Blood sample.</prim_outcome>
      <prim_outcome>LDL. Timepoint: Measurement of the LDL at the beginning of the study and a month, 2 months after finishing Wash Out Diet. Method of measurement: Blood sample.</prim_outcome>
      <prim_outcome>Cholesterol. Timepoint: Measurement of the blood cholesterol at the beginning of the study and a month, 2 months after finishing Wash Out Diet. Method of measurement: Blood sample.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Measurement of the blood triglyceride at the beginning of the study and a month, 2 months after finishing Wash Out Diet. Method of measurement: Blood sample.</prim_outcome>
      <prim_outcome>Anti-hsp27. Timepoint: Measurement of the anti-hsp27 at the beginning of the study and a month, 2 months after finishing Wash Out Diet. Method of measurement: Blood sample.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-12-24</approval_date>
        <contact_name>Human Research Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Mashhad University of Medical Sciences, Azadi square Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
